1311269-23-4

Upstream product

• 1311269-28-9 (3R)-3-[(4-hydroxyphenyl)methyl]-4-[(4-methoxybenzene)sulfonyl]-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine-7-carbonitrile 
• 1311269-32-5 (3R)-3-[(4-hydroxyphenyl)methyl]-4-[(4-methoxybenzene)sulfonyl]-1-[(1-methyl-1H-imidazol-5-yl)methyl]-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine-7-carbonitrile 
• 1311269-26-7 (3R)-7-bromo-3-[(4-hydroxyphenyl)methyl]-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine-2,5-dione 
• 1311269-29-0 (R)-4-((7-bromo-2,3,4,5-tetrahydro-1H-benzo[e][1,4]diazepin-3-yl)methyl)phenol 
• 1311269-30-3 (3R)-3-[(4-hydroxyphenyl)methyl]-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine-7-carbonitrile 
• 4692-98-2 5-bromoisatoic anhydride 
• 3728-20-9 D-tyrosine methylester hydrochloride 
• 98-68-0 4-methoxy-phenyl-sulphonyl chloride 
• 109-65-9 1-bromo-butane 
• 1311269-19-8 (R)-4-((7-(3-chlorophenyl)-4-(4-methoxyphenylsulfonyl)-1-((1-methyl-1H-imidazol-5-yl)methyl)-2,3,4,5-tetrahydro-1H-benzo[e][1,4]diazepin-3-yl)methyl)phenol 

Relevant academic research and scientific papers

Structure-guided development of selective RabGGTase inhibitors

Designing for selectivity: A combination of protein crystal-structure analysis, virtual screening, and synthetic chemistry has been used to develop noncytotoxic inhibitors of RabGGTase (IC50: 42nM for the example shown; red O, blue N, yellow S)